Gennex Laboratories Ltd

Read More

• Gennex Laboratories Ltd. is an Indian pharmaceutical company that manufactures active pharmaceutical ingredients, such as expectorants, muscle relaxants, analgesic, and anti-fungal ingredients. The company was incorporated in 1995, with its manufacturing facility in the Industrial Development Area (IDA), Bollaram, Telangana.

  Gennex Laboratories Ltd. has a total market capitalisation of Rs. 109.55 crore. The share price of the company was at Rs. 8.66 as of April 5, 2022. Gennex Lab shares hit a 52-week high at Rs. 12.90 and recorded a 52-week low at Rs. 3.90. Gennex Lab share price returned a total of 119.24% to investors in a year. The company’s latest price-to-earnings ratio was at 21.71 as of April 5, 2022. The price-to-book ratio was at 0.40 on the same day.

  Gennex Laboratories has a strong foothold in the Indian pharmaceutical market. It also has an active global presence and exports its products to more than 30 countries in five continents, including Asia, Africa, Europe, North America, and South America. Almost 70% of the company’s exports are made to countries, such as the USA, Columbia, Mexico, Pakistan, Iran, Egypt, Jordan, Bangladesh, and others.

  The company’s manufacturing site, located in the IDA, Bollaram, is designed for a multi-product range. It has a mix of different capacities of glass-lined and stainless-steel reactors and various range of auxiliary equipment, including centrifuges and dryers. The manufacturing is done according to the CGMP standards in clean rooms of class 100000.

  For the quarter ended December 31, 2021, Gennex Laboratories Ltd. reported a total income of Rs. 16.68 crore. During the same period in the previous year, the company earned a total income of Rs. 15.61 crore. The company reported a total profit of Rs. 0.79 crore for the quarter ended December 31, 2021, compared to a total profit of Rs. 1.23 crore in the same period in the previous year. Gennex Laboratories announced an earnings per share of Rs. 0.06 for the quarter ended December 31, 2021, compared to an earnings per share of Rs. 0.10 for the same period in the previous year. The public is the major shareholder in the company, holding 77.95% of the total outstanding shares. The promoters of the company hold 22.05%. 

  Disclaimer: ICICI Securities Ltd. (I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is a Member of National Stock Exchange of India Ltd (Member Code :07730), BSE Ltd (Member Code :103) and Member of Multi Commodity Exchange of India Ltd. (Member Code: 56250) and having SEBI registration no. INZ000183631. Name of the Compliance officer (broking): Mr. Anoop Goyal, Contact number: 022-40701000, E-mail address: complianceofficer@icicisecurities.com. Investment in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein above shall not be considered as an invitation or persuasion to trade or invest.  I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. The contents herein above are solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments or any other product. Investors should consult their financial advisers whether the product is suitable for them before taking any decision. The contents herein mentioned are solely for informational and educational purpose.